ImmunityBio, Inc.IBRXNASDAQ
LOADING
|||
Switch Symbol:
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
21.33%
↓ 94% below average
Average (39q)
332.68%
Historical baseline
Range
High:7566.67%
Low:-96.41%
CAGR
-1.6%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 21.33% |
| Q2 2025 | 59.99% |
| Q1 2025 | 118.71% |
| Q4 2024 | 23.68% |
| Q3 2024 | 483.19% |
| Q2 2024 | 2517.50% |
| Q1 2024 | -71.22% |
| Q4 2023 | 69.51% |
| Q3 2023 | 100.00% |
| Q2 2023 | -88.61% |
| Q1 2023 | 393.15% |
| Q4 2022 | -38.14% |
| Q3 2022 | 237.14% |
| Q2 2022 | 150.00% |
| Q1 2022 | -96.41% |
| Q4 2021 | 490.91% |
| Q3 2021 | -80.53% |
| Q2 2021 | 143.88% |
| Q1 2021 | 561.90% |
| Q4 2020 | -86.09% |
| Q3 2020 | -65.37% |
| Q2 2020 | 164.24% |
| Q1 2020 | -82.07% |
| Q4 2019 | 7566.67% |
| Q3 2019 | -29.41% |
| Q2 2019 | 240.00% |
| Q1 2019 | -28.57% |
| Q4 2018 | -77.42% |
| Q3 2018 | 675.00% |
| Q2 2018 | -20.00% |
| Q1 2018 | -58.33% |
| Q4 2017 | 50.00% |
| Q3 2017 | -42.86% |
| Q2 2017 | 27.27% |
| Q1 2017 | -21.43% |
| Q4 2016 | 16.67% |
| Q3 2016 | 0.00% |
| Q2 2016 | 100.00% |
| Q1 2016 | -57.14% |
| Q4 2015 | 40.00% |